About Avidity Biosciences, a Novartis Company
Our mission is to profoundly improve people’s lives by delivering a new class of RNA therapeutics – AOCs – that will treat serious, genetic neuromuscular diseases. Our proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. On February 27, 2026, Avidity Biosciences became an indirect, wholly owned subsidiary of Novartis AG. The acquisition of Avidity was originally announced on October 26, 2025.
News Releases
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
April 17, 2023
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced...
-
April 13, 2023
Nicholas E. Johnson, M.D., M.Sci., FAAN, MARINA lead investigator will present AOC 1001 topline data Volume 7 of investor and analyst series will be an in-person event in Boston and available via...
-
March 30, 2023
Discussions with the FDA ongoing as Avidity submits emerging AOC 1001 data from the MARINA trial AOC 1001 continues to be generally well tolerated; Avidity provides more information on the rare...
-
March 21, 2023
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced...
-
March 13, 2023
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced...